Sprint Bioscience AB (publ) (SPRINT.ST)
SEK 1.6
(0.25%)
SEK 1.6
(0.25%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -845 Thousand SEK | 93.87% |
| 2022 | -60.9 Million SEK | -139.18% |
| 2021 | -25.46 Million SEK | 32.41% |
| 2020 | -37.67 Million SEK | -84.49% |
| 2019 | -20.42 Million SEK | 7.43% |
| 2018 | -22.05 Million SEK | -106.78% |
| 2017 | -10.66 Million SEK | -333.63% |
| 2016 | 4.56 Million SEK | 129.73% |
| 2015 | -15.35 Million SEK | -36.39% |
| 2014 | -11.25 Million SEK | -170.91% |
| 2013 | -4.15 Million SEK | 20.63% |
| 2012 | -5.23 Million SEK | -239.7% |
| 2011 | -1.54 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -5.64 Million SEK | -47.22% |
| 2024 Q3 | -4.5 Million SEK | 4.56% |
| 2024 Q1 | -3.83 Million SEK | 23.58% |
| 2023 Q2 | -11.83 Million SEK | 3.79% |
| 2023 Q3 | 28.43 Million SEK | 340.21% |
| 2023 Q1 | -12.3 Million SEK | 17.92% |
| 2023 Q4 | -5.01 Million SEK | -117.63% |
| 2023 FY | -3.73 Million SEK | 93.87% |
| 2022 FY | -60.9 Million SEK | -139.18% |
| 2022 Q3 | -13.5 Million SEK | 25.6% |
| 2022 Q2 | -18.15 Million SEK | -26.15% |
| 2022 Q4 | -14.99 Million SEK | -11.01% |
| 2022 Q1 | -14.38 Million SEK | 5.01% |
| 2021 FY | -25.46 Million SEK | 32.41% |
| 2021 Q4 | -15.14 Million SEK | -187.65% |
| 2021 Q3 | 17.28 Million SEK | 217.34% |
| 2021 Q2 | -14.72 Million SEK | -13.0% |
| 2021 Q1 | -13.03 Million SEK | 0.08% |
| 2020 Q1 | -9.48 Million SEK | 7.19% |
| 2020 FY | -37.67 Million SEK | -84.49% |
| 2020 Q4 | -13.04 Million SEK | -149.09% |
| 2020 Q2 | -10.07 Million SEK | -6.16% |
| 2020 Q3 | -5.23 Million SEK | 48.0% |
| 2019 Q3 | -8.21 Million SEK | -269.21% |
| 2019 FY | -20.42 Million SEK | 7.43% |
| 2019 Q4 | -10.22 Million SEK | -24.51% |
| 2019 Q2 | 4.85 Million SEK | 172.86% |
| 2019 Q1 | -6.65 Million SEK | 38.33% |
| 2018 Q4 | -10.79 Million SEK | -21.42% |
| 2018 FY | -22.05 Million SEK | -106.78% |
| 2018 Q3 | -8.89 Million SEK | 8.33% |
| 2018 Q2 | -9.7 Million SEK | -232.31% |
| 2018 Q1 | 7.33 Million SEK | 201.41% |
| 2017 Q1 | 1.08 Million SEK | -60.14% |
| 2017 Q2 | 989 Thousand SEK | -8.68% |
| 2017 Q3 | -5.51 Million SEK | -657.13% |
| 2017 Q4 | -7.22 Million SEK | -31.2% |
| 2017 FY | -10.66 Million SEK | -333.63% |
| 2016 Q2 | 4.11 Million SEK | 247.12% |
| 2016 FY | 4.56 Million SEK | 129.73% |
| 2016 Q4 | 2.71 Million SEK | 411.72% |
| 2016 Q3 | 531 Thousand SEK | -87.09% |
| 2016 Q1 | -2.79 Million SEK | 29.86% |
| 2015 FY | -15.35 Million SEK | -36.39% |
| 2015 Q4 | -3.98 Million SEK | -54.87% |
| 2015 Q3 | -2.57 Million SEK | 48.56% |
| 2015 Q2 | -5 Million SEK | -31.74% |
| 2015 Q1 | -3.79 Million SEK | -3.23% |
| 2014 Q4 | -3.67 Million SEK | -38.8% |
| 2014 FY | -11.25 Million SEK | -170.91% |
| 2014 Q1 | -2.36 Million SEK | -233.05% |
| 2014 Q2 | -2.56 Million SEK | -8.19% |
| 2014 Q3 | -2.65 Million SEK | -3.43% |
| 2013 Q3 | -1.32 Million SEK | -24.69% |
| 2013 Q2 | -1.06 Million SEK | 0.0% |
| 2013 Q4 | -711 Thousand SEK | 46.26% |
| 2013 FY | -4.15 Million SEK | 20.63% |
| 2013 Q1 | -1.06 Million SEK | 0.0% |
| 2012 FY | -5.23 Million SEK | -239.7% |
| 2011 FY | -1.54 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 99.661% |
| Ziccum AB (publ) | -21.56 Million SEK | 96.081% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 94.848% |
| BioArctic AB (publ) | 252.64 Million SEK | 100.334% |
| Mendus AB (publ) | -100.65 Million SEK | 99.16% |
| Genovis AB (publ.) | 54.22 Million SEK | 101.558% |
| Intervacc AB (publ) | -93.57 Million SEK | 99.097% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | 94.553% |
| Active Biotech AB (publ) | -46.48 Million SEK | 98.182% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 104.692% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 98.475% |
| Aptahem AB (publ) | -10.1 Million SEK | 91.638% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 99.737% |
| Kancera AB (publ) | -65.04 Million SEK | 98.701% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 99.372% |
| Fluicell AB (publ) | -26.87 Million SEK | 96.856% |
| Saniona AB (publ) | -81.06 Million SEK | 98.958% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | 93.17% |
| Biovica International AB (publ) | -126.07 Million SEK | 99.33% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 98.012% |
| AcouSort AB (publ) | -17.48 Million SEK | 95.168% |
| Xintela AB (publ) | -57.23 Million SEK | 98.524% |
| Abliva AB (publ) | -96.54 Million SEK | 99.125% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 99.74% |
| Karolinska Development AB (publ) | -3.5 Million SEK | 75.892% |
| OncoZenge AB (publ) | -15.9 Million SEK | 94.686% |
| Amniotics AB (publ) | -29.07 Million SEK | 97.094% |
| 2cureX AB (publ) | -36.36 Million SEK | 97.676% |
| CombiGene AB (publ) | -36.3 Million SEK | 97.673% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | 94.228% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 99.78% |
| Camurus AB (publ) | 532.35 Million SEK | 100.159% |
| Corline Biomedical AB | -1.78 Million SEK | 52.74% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 99.533% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 97.973% |
| I-Tech AB | 24.43 Million SEK | 103.458% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 99.893% |
| Cyxone AB (publ) | -21.66 Million SEK | 96.099% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 99.203% |
| Biosergen AB | -27.26 Million SEK | 96.901% |
| Cantargia AB (publ) | -290.01 Million SEK | 99.709% |
| NextCell Pharma AB | -43.17 Million SEK | 98.043% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 99.533% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 95.057% |
| Nanologica AB (publ) | -69.96 Million SEK | 98.792% |
| SynAct Pharma AB | -224.49 Million SEK | 99.624% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 98.087% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 96.472% |
| LIDDS AB (publ) | -40.67 Million SEK | 97.923% |
| Lipum AB (publ) | -37.25 Million SEK | 97.732% |
| BioInvent International AB (publ) | -369.94 Million SEK | 99.772% |
| Alzinova AB (publ) | -16.52 Million SEK | 94.886% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 99.667% |
| Pila Pharma AB (publ) | -6.39 Million SEK | 86.783% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 99.266% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 95.804% |
| Simris Alg AB (publ) | -36.63 Million SEK | 97.693% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 99.423% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 99.728% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 99.238% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | 92.694% |